Bristol Myers Squibb To Present Late-Breaking Data For Breyanzi In Relapsed Or Refractory Follicular Lymphoma And Mantle Cell Lymphoma At 2023 International Conference On Malignant Lymphoma
Portfolio Pulse from Happy Mohamed
Bristol Myers Squibb announced the acceptance of two late-breaker abstracts for Breyanzi studies TRANSCEND FL and TRANSCEND NHL 001 for patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma, respectively, for presentation at the 2023 International Conference on Malignant Lymphoma.
May 30, 2023 | 1:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's Breyanzi studies TRANSCEND FL and TRANSCEND NHL 001 have been accepted for presentation at the 2023 International Conference on Malignant Lymphoma, highlighting the potential of Breyanzi in treating B-cell malignancies.
The acceptance of the two late-breaker abstracts for Breyanzi studies at the 2023 International Conference on Malignant Lymphoma demonstrates the potential of the drug in treating B-cell malignancies. This could lead to increased interest and investment in Bristol Myers Squibb, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100